Cure8 news brief
Links between GWAS risk loci and the specific cell types where those loci may act can focus laboratory experiments and eventually help identify causal genes or pathways relevant to Crohn’s disease.
Researchers studying IBD genetics and cellular mechanisms; clinicians interested in the biological basis of Crohn’s; patients and advocates following research on disease causes and future therapeutic targets.
Researchers analyzed 71 biopsy samples (terminal ileum and ascending colon) from 39 people (23 Crohn’s patients, 16 controls), profiled open chromatin across ~178,000 cells, and defined ~557,000 candidate regulatory regions.
Statistical overlap between known IBD risk loci and cell-type–specific open chromatin showed enrichment mainly in immune cells—especially adaptive T cells, but also B cells, NK cells and innate myeloid cells in Crohn’s. The authors identified ~30 noncoding variants that fall within candidate regulatory elements as prioritized leads for follow-up experiments.
The study is a basic research, not a clinical trial. Key limitations noted by the authors include the modest number of independent individuals (39), sampling limited to ileum and ascending colon, and reliance on European-ancestry GWAS reference data.
Open chromatin at a site does not prove that a variant changes a particular gene’s expression or causes disease; functional follow-up is needed.
This is a single-cell regulatory (ATAC‑seq) study reported as basic research; it does not demonstrate causal effects of the prioritized variants and is limited by sample size, tissue sites sampled, and ancestry of reference GWAS data.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The work helps bridge genetic association signals and the specific immune cells in the intestine where they may act, offering new candidate genes and a method that can probe rare cell types important to IBD biology.
Genetic ancestry can influence IBD risk and disease course, and most prior studies focused on European populations.
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.
